Pre-Conference Workshop
Wednesday 31st March 2004
OPTIONAL WORKSHOP
14.30-18.30
Biotechnology: From the Benchtop to the Boardroom
The Key Steps for Early Stage Commercialization for Pre-Phase II Opportunities
Led by: Stan Yakatan, Chairman & Seth Yakatan, Partner, Katan Associates
John N. Vournakis, Ph.D., Vice President for Research and Development, Marine Polymer Technologies, inc. and Profesor of Graduate Studies at the Medical University of South Carolina

This workshop provides a comprehensive framework for understanding & putting into practice the key elements to commercialization.

For a full overview of this Workshop <click here>
  Day One
Thursday 1st April 2004
07.45
Registration
08.25
Chairman’s Welcome:
P. Louis Myers, Ph.D., Principal
Fish & Richardson P.C
08.30-09.20
OPENING PANEL: Venture Financing Outlook for Biotech in 2004
Chair: Michael Lytton, General Partner, Oxford BioScience Partners
Jean M. George, General Partner, Advanced Technology Ventures
Dr. Christoph H. Westphal, General Partner, Polaris Venture Partners
James M. Garvey, CEO and Managing Partner, Schroder Ventures Life Sciences
PRIVATE EQUITY AND THE LISTED MARKETS
09.20
Stelios Papadopoulos, Ph.D., Vice Chairman,
SG Cowen Securities Corporation
09.40-10.25
PANEL: Capital Markets
Michael King, Managing Director, Healthcare Group, Banc of America
R. Nelson Campbell, Senior Vice President, Life Sciences Investment Banking,
Friedman, Billings, Ramsey
Dr. Sam Fazeli, Senior Biotechnology Analyst, Nomura
10.25
Break
10.45-12.45
BALLROOM:
Small-Cap/
Listed Company Presentations
Chair: P. Louis Myers, Ph.D., Principal
Fish & Richardson P.C		 VENETIAN ROOM:
Small-Cap/
Listed Company Presentations
Chair: Roger Feldman, Principal
Fish & Richardson P.C
12.45
Lunch
BIOPARTNERING & COLLABORATION
14.00-14.50
PANEL: Evolving Pharma/Biotech Relationships
Chair: Eileen Smith Ewing, Esq.,
Partner and Chair of the Life Sciences Practice Group, Kirkpatrick & Lockhart LLP
Dr Maggie Flanagan, Ph.D., Global Alliance Director, Enabling Science and Technology, AstraZeneca Pharmaceuticals
Jan van Heek, Executive Vice President, Therapeutics & Genetics, Genzyme Corporation.
Dr. Jeremy Levin, Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research
Dr. Ravi Kiron, Global Head, Strategic Analysis & Knowledge Management Strategic Alliances, Pfizer Global R&D
SECTOR WORKSHOPS: EARLY-STAGE COMPANY PRESENTATIONS
15.00-16.35

Workshop I:
Immunology / Oncology
Chair: Donna L. LaVoie,
President & CEO,
LaVoie Strategic Communications
Group, Inc.

 Workshop II:
Therapeutics

Workshop III:
Post-Genomics
Opexa Pharmaceuticals, Inc.
MethylGene, Inc.
Hybrigenics SA
BioVex Limited
Munich Biotech AG
Aureon Biosciences Corporation
Genstruct, Inc.
 Nuevolution A/S
Biota, Inc.
Predix Pharmaceuticals Holdings, Inc.
Newron Pharmaceuticals SpA
Oxxon Pharmaccines Ltd
Viral Therapeutics, Inc.
NeuroMed Technologies Inc		 Serenex, Inc
atugen AG
Cellectis SA
Global Genomics AB
GenOdyssee S.A.
Norgen Biotek Corporation
Chronogen, Inc.
FUND OF FUNDS
16.45-17.30
PANEL: Fund of Funds
Chair: William C. Mills III, Partner, Advent International
Matthew I. Hermann, Director, Strategic Health Venture Investing,
Ascension Health Ventures
Gregory V. Stento, Managing Director, HarbourVest Partners, LLC
Robert E. Mast, Managing Director, Monument Group
Otello Stampacchia, Ph.D., Head of Life Sciences Investments, NIB Capital Private Equity
GLOBAL DEVELOPMENT
17.30-18.30
PANEL: Global Development
International Perspectives on Venture Investing & the Development of Regional Life Science Markets
Chair: N. Peter Kostopulos, Leader BioAlliance Practice & Partner Life Sciences,
Womble Carlyle Sandridge & Rice PLLC
Pierre Cantin, Partner, Biotechnology & Life Sciences, CDP Capital – Technology Ventures
Mark R. Saunders, President, Global Markets Capital Group, LLC
Ian Nisbet, Ph.D., Senior Director, Oncology Alliance Management and EU Strategic Marketing, Millennium Pharmaceuticals, Inc.
Antoine Papiernik, General Partner, Sofinnova Partners
18.30
COCKTAIL PARTY

Day Two
Friday 2nd April 2004
07.45
Registration
08.25
Chairman’s Welcome
Dr. Hans A. Küpper, Partner
Global Life Sciences Ventures
TECHNOLOGY TRANSFER
08.30
Theodore J. Roumel, Office of Technology Transfer
National Institutes of Health
08.45-09.30
PANEL: Technology Transfer
Successfully Transferring Technology into the Marketplace
Chair: Lita Nelsen, Director, Technology Licensing Office,
Massachusetts Institute of Technology
O. Prem Das, Ph.D., Director, Office of Technology Licensing & Industry Sponsored Research Harvard Medical School
Dr. John Burt, Head Medical Sciences Team, Imperial College Innovations
Jean Pierre Saintouil, Director, Office of Technology Transfer,
INSTITUT PASTEUR– Paris, France
09.30-10.30
KEYNOTE PANEL: Value Creation in Biotechnology
Introduced by: Hoda Abou-Jamra, Founder & CEO, BioExec Ventures
Chair: Jean-François Formela, Senior Partner, Atlas Venture
Chair: Dr. Ansbert Gadicke, Founding General Partner, MPM Capital
Noubar B. Afeyan, Senior Managing Director & CEO, Flagship Ventures
Steven Holtzman, CEO, Infinity Pharmaceuticals
Dr. Edward. M. Scolnick, President Emeritus, Merck Research Laboratories
10.30
Break
SECTOR WORKSHOPS: COMPANY PRESENTATIONS
10.45-12.30

Workshop IV:
Immunology / Oncology
Immunitor USA, Inc.
Therion Biologics Corporation
Cyclacel Limited
Cytopia Pty Ltd.
Hudson Health Sciences
Point Therapeutics
Post Genomics
Eidogen
Gene Express, Inc.

 Workshop V:
Therapeutics
BIOCORTECH
Dermatrends, Inc
Concurrent Pharmaceuticals
Quorex Pharmaceuticals, Inc.
ConjuGon, Inc.
Transave, Inc.
CombinatoRx, Inc.
Zelos Therapeutics Inc.
12.45
Lunch
14.00
KEYNOTE PRESENTATION:
Biotech 2004: An Industry "Back on Track"
G. Steven Burrill, CEO
Burrill & Company
DRUG DISCOVERY & DEVELOPMENT
14.15
PANEL: Clinical Trials & Drug Development
Assessing the Cost of Clinical Trials & Identifying The Key Issues in Drug Development
Richard E. Kuntz, MD, M, Chief Scientific Officer, Harvard Clinical Research Institute, Chief, Division of Clinical Biometrics, Brigham & Women’s Hospital, Associate Professor of Medicine, Harvard Medical School
14.30-15.30
PANEL: Systems Biology
Is This The Right Time To Invest?
Chair: Dr. James Fickett, Director, Strategic Capabilities, Discovery IS and Informatics, AstraZeneca Pharmaceuticals
Stephen Ober, President, Beyond Genomics, Inc.
Dr. Robert Mashal, Partner, Boston Millennia Partners
Robert Mulroy, President & CEO, Merrimack Pharmaceuticals
EMERGING MARKETS
15.30-16.30
PANEL: Emerging Markets
Examining The Growth of Biotech Industries in Asia-Pacific, Australia, China, India
Chair: Stan Yakatan, Chairman, Katan Associates
Dr. Vibha Ahuja, Deputy General Manager, Biotech Consortium India Limited
Dr. Gurinder S. Shahi, MBBS, PhD, MPH, CEO and Principal Consultant, BioEnterprise Asia
Mario Gobbo, Head of Life Sciences, International Finance Corporation
Dr. Nathan Zhang, President, China ChipScreen Biosciences
16.15
Close of Conference
Back to top